CAS 668467-91-2: 1H-Indole-2,3-dione, 5-chloro-1-[(2,5-dichlorophenyl)methyl]-,3-(O-acetyloxime)

LDN-57444 is a reversible, competitive proteasome Uch-L1 inhibitor(IC50=0.88 μM) .

LDN-57444

LDN-57444 is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR) and inhibits its activation. LDN-57444 is being developed for the treatment of squamous cell carcinoma, which is a type of skin cancer. The drug has been shown to inhibit tumor growth in animal models by inhibiting body formation, promoting autophagy, and reducing mitochondrial membrane potential. LDN-57444 has also been shown to inhibit the proliferation of human cancer cells in vitro and decrease cardiac arrhythmias. LDN-57444 binds to EGFR with a hydroxyl group on its structure that interacts with the EGFR's active site. This binding prevents EGFR from activating downstream signaling pathways, such as those involving phosphatidylinositol 3-kinase (PI3K) and Akt kinase, which are involved in cell proliferation and survival.